Open Targets Platform

Integrates genetic, genomic, pharmacological evidence to score targets for 20k+ diseases.

Composite

100.0

Experimental validation

Wet-lab confirmed

Stages

Disease ModelingTarget ID

Modalities

cross-modality

Task types

target-disease-associationprioritization

Size

targets: 63,000
diseases: 28,000
evidence: 18,000,000

License

CC0 / Apache-2.0

First release

2016-12

Last updated

2025-06

Official site

→ project page

Leaderboard

→ leaderboard

Dataset

→ dataset

Code / GitHub

→ repository

HuggingFace

→ HF

Paper

The Open Targets Platform: supporting systematic drug-target identification and prioritisation · Ochoa D, Hercules A, Carmona M, et al. · 2021 · paper · doi:10.1093/nar/gkaa1027 · 1,100 citations

Flags

none

Experts

Ian Dunham, Ellen McDonagh

Groups

Open Targets, EMBL-EBI, GSK Computational Biology, Wellcome Sanger Institute

Hosted by

ELIXIR Infrastructure

Related benchmarks

DepMap (Cancer Dependency Map), DisGeNET, PrimeKG

Rubric (7-criterion)

rigor

coverage

maintenance

adoption

quality

accessibility

industry_relevance

Notes

Industry gold standard for target prioritization. Quarterly versioned releases.

← Back to all benchmarks

Compare:

Open comparison →